+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

Gastric Neuroendocrine Tumors Pipeline Analysis Report 2025 - Product Thumbnail Image

Gastric Neuroendocrine Tumors Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Gastric Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Gastric Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Esophageal Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Esophageal Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Bone Metastasis Pipeline Analysis Report 2025 - Product Thumbnail Image

Bone Metastasis Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Biliary Tumors Pipeline Analysis Report 2025 - Product Thumbnail Image

Biliary Tumors Pipeline Analysis Report 2025

  • Report
  • June 2025
  • 200 Pages
  • Global
From
Oncology Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Oncology Drug Market - Forecasts from 2025 to 2030

  • Report
  • June 2025
  • 141 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
Stomach Cancer Market - Product Thumbnail Image

Stomach Cancer Market

  • Report
  • September 2025
  • 150 Pages
  • Global
From
From
Precision Cancer Therapeutics, 2022 - Product Thumbnail Image

Precision Cancer Therapeutics, 2022

  • Report
  • November 2022
  • 154 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more